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Abstract Two epithelial tumour lines, HeLa and KB, were 
treated with okadaic acid and calyculin A, specific inhibitors of 
Ser/Thr phosphatases (PP), esp. PP1 and PP2A. Morphological 
criteria, analysis of DNA fragmentation and studies of 
membrane integrity revealed that both agents concentration-
and time-dependently induced apoptosis at nanomolar concen-
trations which in these cells was associated with the stimulation 
of a transglutaminase activity. Since a non-functional derivative 
of okadaic acid did not affect cell viability apoptosis was 
apparently related to the inhibition of PP1 and PP2A. 
Membrane damage marker activity was delayed by at least 
24 h when compared to nuclear alterations. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Apoptosis is an essential process in growth, development 
and tissue homeostasis of multicellular organisms. Character-
istic features are viability loss, DNA fragmentation and mem-
brane blebbing accompanied by sustained membrane integ-
rity. As an active process apoptosis requires an intact 
metabolism and in some cells RNA and protein synthesis 
[1-1]. 
Certain cell lines respond with apoptosis when Ser/Thr 
phosphatases are continuously inhibited for more than 
12-24 h by agents like okadaic acid, cantharidic acid and 
calyculin A [5,6]. These changes can be followed by viability 
assays, nuclear and cytosolic morphological appearance, 
DNA fragmentation analysis and flow cytometry. A possible 
target of inhibitors of Ser/Thr phosphatases, esp. of PP1 and 
PP2A, as inducers of apoptosis seems to be the control of the 
cell cycle which requires the coordinated phosphorylation and 
dephosphorylation of regulatory proteins. Inhibition of Ser/ 
Thr phosphatases by okadaic acid has been reported to result 
in cell cycle deviation with subsequent progression into apop-
tosis [7]. In addition, in a histiocytic lymphoma line resistant 
to tumour necrosis factor (TNF) induced apoptosis okadaic 
acid and calyculin A as specific inhibitors of Ser/Thr phospha-
tases synergized with TNF. In combination with these agents 
TNF triggered apoptosis in the initially resistant cells [8]. 
A characteristic feature of apoptosis even in cultured cells is 
the presence of gross structural changes but in contrast to 
necrosis still intact membrane function which seems to be 
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necessary for the encapsulation of cellular components and 
debris in definite structures, so-called apoptotic bodies. This 
structural behaviour underlies the observation that apoptotic 
cell death does not affect neighbouring cells and therefore is 
not accompanied by inflammatory responses [1,9,10]. An im-
portant factor involved is presumed to be the activation or 
induction of a tissue transglutaminase that modulates mem-
brane texture [11,12]. Such an increase in transglutaminase 
activity has not always been reported for agents that induce 
apoptosis [13,14]. For example in neuroblastoma cells apop-
tosis induction by cisplatin and retinoic acid but not by 
okadaic acid was accompanied by an increased transglutamin-
ase activity [13]. 
Studies in cultured cells are complicated by the fact that 
secondary necrosis with leaky membranes follows initial apop-
tosis. In asynchronously growing cultures this might result in 
some association of apoptotic markers (e.g. DNA fragmenta-
tion, apoptotic body formation) with cytosolic enzyme release, 
e.g. of LDH, in the medium albeit kinetic differences in the 
appearance of apoptosis and necrosis markers would be ex-
pected. 
We studied the effects of okadaic acid and calyculin A on 
three different human epithelial tumour lines (HeLa, KB, 
MCF-7). Both agents have been isolated from marine organ-
isms [15,16] and produce diarrhetic shellfish poisoning. These 
toxins specifically inhibit Ser/Thr phosphatases, predomi-
nantly types 1 and 2A, at nanomolar concentrations [17-19] 
whereas PP2B and PP2C are not inhibited at submicromolar 
concentrations. While okadaic acid inhibits PP2A with an 
IC50 of about 0.5-1 nM, PP1 is about 10-30-fold less sensitive 
(IC50 15-50 nM) [17-19]. Calyculin A inhibits both enzymes 
with IC50 values of 1-2 nM [17-19]. 
Here, we report for the first time that apoptosis induction in 
two epithelial human tumour lines by okadaic acid and caly-
culin A, inhibitors of Ser/Thr phosphatases, is concentration-
dependently correlated with an increased transglutaminase ac-
tivity. Our conclusion is supported by the observation that 
maximum membrane damage as measured by lactate dehydro-
genase release was delayed by 24 h when compared to max-
imum DNA fragmentation. 
2. Materials and methods 
2.1. Materials 
Cell culture reagents were from Seromed (Berlin, Germany), Boeh-
ringer-Mannheim (Mannheim, Germany) and Life Technologies 
(Eggenstein, Germany). Okadaic acid and calyculin A were purchased 
from RBI (Biotrend, Koln, Germany) and okadaic acid tetraacetate 
from Calbiochem (Bad Soden, Germany). [14C]Putrescine-dihydro-
chloride (80-120 mCi/mmol) was from NEN Du Pont (Dreieich, 
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Germany) and unlabelled putrescine from Sigma (Deisenhofen, Ger-
many). 
2.2. Cell culture 
Cervix carcinoma HeLa [20], pharynx carcinoma KB [21] and mam-
mary epithelial carcinoma MCF-7 [22] cells were cultured in Dulbec-
co's modified Eagle's medium (DMEM) supplemented with 7.5% foe-
tal bovine serum, penicillin (100000 U/l), streptomycin (100 mg/1) and 
amphotericin B (250 Ug/1). Treatment of cells was performed in serum-
free insulin-transferrin-selenite (ITS) supplemented DMEM without 
phenol red. 
2.3. MTT viability assay 
Cells (20 X 104/well) were plated in 96-well plates and cultured for 
48 h in complete medium. Then medium was changed to ITS with the 
individual treatments. After 24 h 10 ul of thiazolyl blue (MTT 5 mg/ 
ml, Sigma, Deisenhofen, Germany) were added for 1 h. Cells and the 
converted dye were lysed with 20% SDS in 0.02 N HC1 for 24 h at 
37°C. Mitochondrial conversion to the formazan product was quan-
tified in an ELISA reader (Molecular Devices, USA) at 550 nm. 
Values of treated cells were presented as percent of the respective 
controls. 
2.4. Lactate dehydrogenase activity 
Lactate dehydrogenase (LDH) in medium (20 ul) was measured at 
365 nm in an Eppendorf photometer by following the oxidation of 
NADH to NAD accompanying the conversion of pyruvate into lac-
tate [23]. LDH activity was calculated from the mean AE/min in the 
linear range according to the Lambert-Beer law. 
2.5. Quantitative DNA fragmentation assay 
The assay procedure was modified from reported methods [24-26]. 
Cells (0.7-0.9 X106) were plated in 6-cm dishes. After a 24 h treatment 
the supernatant (medium) was removed and centrifuged for 3 min at 
120Xg (4°C). The pellet was resuspended with the adherent cells 
which were scraped off the plates. The cell pellet was lysed for 
30 min at room temperature with lysis buffer (5 mM Tris-HCl 
(pH 8), 20 mM EDTA, 0.5% Triton X-100). Low molecular weight 
DNA was separated from the genomic DNA by centrifugation at 
14000Xg for 20 min. The supernatant was transferred into another 
vial containing perchloric acid (PCA, 11.6 N) resulting in a final 
concentration of 1.5 N PCA. The pellet was dissolved in 1.5 N 
PCA. Protein was precipitated by heating to 80°C for 15 min followed 
by centrifugation (1500Xg, 10 min). DNA in 125 JJ.1 of cleared super-
natant or pellet mixture was quantified by its deoxyglucose content 
[27,28] at 600 nm. Herring sperm DNA (0.4 mg/ml in 5 mM NaOH) 
was used for standards (0-200 ug/ml). The DNA fragmentation rate 
was calculated from the ratio of DNA in the supernatant to total 
DNA. 
2.6. Transglutaminase assay 
Quantification of transglutaminase activity followed the methods of 
[12] and [29]. Cells (2-3 X106) were cultured in 10-cm dishes for 24 h 
under the individual conditions. Then medium was discarded and cells 
lysed in 150 ul of lysis buffer (150 mM Tris-HCl (pH 7.2), 1 mM 
EDTA, 0.5% Triton X-100). Transglutaminase activity of each sample 
was measured after two reaction periods (10 and 70 min) with dimeth-
ylcaseine as substrate and labelled putrescine. Conditions per reac-
tion (100 ul) were 3 mg/ml dimethylcaseine, 5 mM DTT, 0.2 uCi 
[14C]putrescine (0.5 uM), 5 mM CaCl2 and 100-150 ug extract protein 
at pH 7.5. Negative controls contained EDTA instead of CaCL.. Re-
actions at 37°C were stopped after 10 and 70 min by the addition of 
1 ml of ammonium sulfate (35%). After 15 min at room temperature 
the precipitated protein was pelleted by centrifugation at 14000Xg 
for 5 min. The supernatant was discarded and the pellet washed with 
0.5 ml of ammonium sulfate. Following a second centrifugation the 
pellet was dissolved in 300 ul of water. Incorporation of activity into 
the substrate was quantified by liquid scintillation counting after ad-
dition of 4 ml of scintillation cocktail (Instant Scint, Packard, Frank-
furt, Germany) to 280 ul of dissolved pellet. Activity was calculated 
from the difference between the 70 and 10 min values. As a positive 
control a purified transglutaminase (Sigma, Deisenhofen, Germany) 
was used at concentrations from 1.25 to 320 mU/ml. Protein was 
measured in 10 ul of the extract by the biscinchonic acid assay (Pierce, 
Rockford, USA) with bovine serum albumin as standard. 
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Fig. 1. Viability of HeLa (circles), KB (triangles) and MCF-7 
(squares) cells following a 24 h treatment with calyculin A (A) and 
okadaic acid (B). Open symbols in (B) are viabilities of cells treated 
with okadaic acid tetraacetate, the non-functional derivative of 
okadaic acid. Means ± SEM of 6-8 experiments. 
3. Results and discussion 
HeLa and K B cells concentration-dependently respond with 
a decreased viability to a 24 h treatment with okadaic acid 
and calyculin A (Fig. 1A,B). In contrast, MCF-7 cells were 
nearly unresponsive to both treatments (Fig. 1). In our experi-
ments both responsive lines displayed a maximal 60-70% de-
crease in mitochondrial conversion of the tetrazolium dye 
M T T while in MCF-7 cells even high concentrations of caly-
culin A ( > 1 0 nM) reduced viability only by about 20%. 
Okadaic acid toxicity was seen above 25 n M , while calyculin A 
induced comparable changes at 8-10-fold lower concentra-
tions ( > 2 . 5 nM). Okadaic acid tetraacetate, a derivative not 
inhibiting PP1 and PP2A [18] did not reduce viability in both 
responsive lines (Fig. IB). 
Within the same concentration range both agents induced 
morphological changes resembling apoptosis induction. More 
and more cells developed characteristic membrane Webbings 
and became rounded and condensed (Fig. 2a-d) . Therefore, 
treatment for more than 12 h with okadaic acid and calycu-
lin A can (HeLa, KB) but also may not (MCF-7) induce 
apoptosis at the tested concentrations and the according peri-
ods of treatment. 
Qualitative analysis of D N A fragmentation revealed in K B 
and HeLa cells the D N A ladder phenomenon resulting from 
internucleosomal D N A cleavage [31] usually observed in 
apoptotic cells, but no comparable alterations in MCF-7 cells 
(data not shown). To study the concentration-dependencies in 
more detail a quantitative D N A fragmentation analysis of 
cells treated with the phosphatase inhibitors was performed 
by measuring the appearance of low molecular weight D N A 
(Fig. 3A,B). After 24 h HeLa and K B cells responded with an 
increase in fragmented D N A up to 20% (okadaic acid) and 
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Fig. 2. Phase contrast microscopy (200-fold magnification) of KB (a,b) or HeLa (c,d) cells treated with 50 nM okadaic acid (a,c) or 7.5 nM 
calyculin A (b,d). 
12-14% (calyculin A) while MCF-7 cells revealed no compa-
rable rise in DNA cleavage under the same conditions. Inter-
estingly, in both responsive tumour lines the fragmentation 
rate levelled off at 15 nM calyculin A. Higher concentrations 
of this agent did not result in maximal fragmentation rates 
comparable to that seen with okadaic acid. These observa-
tions differed from those with GH3 cells, a rat pituitary line. 
In these cells both inhibitors induced the same extent of DNA 
fragmentation with a comparable concentration ratio of 10:1 
between okadaic acid and calyculin A [5]. This observation 
supports the assumption that apoptosis induction by inhibi-
tors of Ser/Thr phosphatases is a phenomenon seen with 
many but not all cells and in addition that cell-specific differ-
ences exist even between individual responsive lines. The miss-
ing sensitivity of MCF-7 cells for okadaic acid cytotoxicity 
was further confirmed by staining DNA with a fluorescent 
dye, which showed the typical nuclear fragmentation and con-
densation in KB and HeLa cells treated with 150 nM okadaic 
acid, but no changes in MCF-7 cells. These findings are sup-
ported by observations of Oberhammer et al. [30] with four 
different epithelial cell lines. The hormone-sensitive MCF-7 
cells were the only line which did not respond with apoptosis 
to serum withdrawal or to TGF-(3 or etoposide treatment. The 
observed lack of sensitivity of the MCF-7 cells might be the 
result of high endogenous levels of antiapoptotic factors, e.g. 
Bcl-2 [32], or decreased intracellular accumulation of the drug 
as the result of increased drug extrusion, e.g. by the P-glyco-
protein mediating multidrug resistance [33]. 
DNA fragmentation analysis of cells treated with okadaic 
acid tetraacetate (150 nM) revealed no signs of cellular dam-
age by this non-functional derivative with fragmentation rates 
of 1.4 ±0.3% (KB) and 2.0 ±0.8% (HeLa) vs. 1.7 ±0.5% (KB) 
and 2.0 ±0.4% (HeLa) in untreated cells while 150 nM 
okadaic acid induced rates of 18.6 ±1.3% (KB) and 23.5 ± 
0.9% (HeLa). Taken together with the data from the viability 
assays (Fig. IB) these results substantiate the hypothesis that 
prolonged inhibition of PP1 and/or PP2A triggers apoptosis. 
A rise in tissue transglutaminase activity has been described 
as a prominent feature of some cells undergoing chemically 
induced apoptotic cell death [12,29,34-37]. This activity is 
considered to be important for the organised involution of 
apoptotic cells which does not negatively affect and thus ren-
ders protection for the surrounding tissue. Okadaic acid in-
duced apoptosis was described for many different cells 
[5,6,32,38] albeit no concomitant activation of transgluta-
minase activity was observed [13,14]. Other apoptotic signals, 
e.g. retinoic acid, resulted in apoptosis in the same cell lines 
which was associated with an enhanced transglutaminase ac-
tivity [13,14]. To address a relation between apoptosis and 
transglutaminase activation in our systems we studied trans-
glutaminase activity in the okadaic acid and calyculin A re-
sponsive KB and HeLa cells. In contrast to previous reports 
an increased transglutaminase activity was observed in ex-
tracts from okadaic acid and calyculin A treated HeLa and 
KB cells (Fig. 4). Both lines displayed a concentration-de-
pendent increase which correlated with the concentration-de-
pendency for DNA fragmentation. While the concentration 
response to the phosphatase inhibitors was comparable, basal 
transglutaminase activity was different. HeLa cells displayed a 
2-fold higher basal activity ( = 300 mU/mg protein) with a 
treatment associated activation by 2 (calyculin A) to 2.5-fold 
(okadaic acid). Basal activity in KB cells was lower (165 mU/ 
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mg protein) but comparably activated by 2.3- and 4-fold by 
calyculin A and okadaic acid, respectively. Again the effects 
of calyculin A were observed at about 10-fold lower concen-
trations. Calyculin A which produced a lower maximal DNA 
fragmentation also activated transglutaminase to a lower ex-
tent in both lines. Thus, two different biochemical markers of 
apoptosis induction, transglutaminase activation and DNA 
fragmentation, gave comparable results when calyculin A 
and okadaic acid, two structurally and functionally different 
inhibitors of Ser/Thr PP1 and PP2A, were studied. 
As a functional assay substantiating that the initial cyto-
toxic effects of okadaic acid and calyculin A are apoptotic and 
not necrotic we compared the time course of DNA fragmen-
tation with that of lactate dehydrogenase release as a marker 
of membrane integrity. Both cell lines were treated for up to 
96 h with 50 nM okadaic acid, a concentration that resulted 
only in a slight increase in DNA fragmentation (Fig. 3B) and 
cell death (Fig. IB) but marked morphological alterations 
(Fig. 2a,c) after 24 h. With this concentration a marked 
more than 30% DNA fragmentation was observed after 48 h 
in both lines (Fig. 5A,B). LDH release as a marker of 
membrane damage reached its maximal values 24-48 h later. 
This delayed release of a cytosolic enzyme can be considered 
to be the consequence of the co-ordinated packing and sal-
vage of intracellular components characteristic for apoptosis 
which was suggested to result from transglutaminase activa-
tion [39]. 
It has been reported that cells undergo apoptosis from a 
defined point of the cell cycle depending on the individual 
substance inducing apoptosis [13,39-41]. The rise in LDH 
release at 48 h might be explained by the fact that in our 
asynchronously growing cultures the cells develop apoptosis 
also in an asynchronous way. Therefore, at the peak of DNA 
fragmentation some cells already could have passed apoptosis 
and would have proceeded to secondary necrosis, if they were 
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Fig. 3. DNA fragmentation in HeLa (circles) or KB (triangles) cells 
after a 24 h incubation with the indicated concentrations of calycu-
lin A (A) and okadaic acid (B). Means ± SEM of 4-5 experiments. 
Fig. 4. Activation of a tissue transglutaminase activity in HeLa 
(circles) and KB (triangles) cells following a 24 h incubation with 
calyculin A (open symbols) or okadaic acid (filled symbols). Means 
±SEM of 5 measurements. Basal activities are given by the lines 
and were 165 mU/mg protein (KB cells, solid line) and 300 mU/mg 
protein (HeLa cells, broken line). 
at the susceptible point of the cell cycle when the inhibitor was 
added. Even after dissolution into apoptotic bodies the mem-
brane integrity is initially preserved. In cell culture secondary 
necrosis, during which the apoptotic bodies go through a 
swelling process, follows initial apoptosis since no subsequent 
phagocytosis occurs [1]. This might be the reason that after 48 
h LDH activity increases in the medium (Fig. 5A,B) despite 
the fact that transglutaminase was activated. 
Calyculin A was more potent than okadaic acid but con-
centrations above 15 nM resulted in less prominent apoptotic 
features (lower fragmentation rate, cellular swelling instead of 
condensation). Therefore, we would suggest that these concen-
trations induce necrotic instead of apoptotic features. Such 
concentration-dependent differences in cytotoxicity either as 
apoptosis at lower or necrosis at higher concentrations have 
been reported for many physical and chemical cytotoxic stim-
uli [4]. Whether the observations of necrotic characteristics 
with HeLa and KB cells are the consequences of a small 
apoptotic concentration window for calyculin A or a fast de-
veloping secondary necrosis following an initial apoptosis can-
not definitely be answered. 
In summary, okadaic acid and calyculin A, two structurally 
different inhibitors of Ser/Thr PP1 and PP2A, induced apop-
tosis in HeLa and KB cells, two human epithelial cancer lines. 
Under the same conditions no comparable toxicity was ob-
served with MCF-7 breast tumour cells. Okadaic acid tetra-
acetate, a derivative of okadaic acid that does not inhibit 
phosphatases did not induce apoptosis. When comparing the 
concentration-response to okadaic acid and calyculin A con-
sistently a discrepancy by 8-10-fold was observed between 
both drugs. This is most likely caused by the differences in 
their affinities towards PP1 and PP2A. Calyculin A inhibits 
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Fig. 5. Kinetics of DNA fragmentation (filled symbols) and LDH 
release (open symbols) in HeLa (A) and KB (B) cells treated with 
50 nM okadaic acid. Means ± SEM of 3 experiments. 
PP1 and PP2A at a similar concentration range while okadaic 
acid inhibits PP1 at about 10-30-fold higher concentrations 
than PP2A which is in accordance with the concentrations 
( > 50 nM) necessary for triggering apoptosis after 24 h. 
Apoptosis induction seems to be related to the preferential 
inhibition of PP1 or the simultaneous inhibition of PP1 and 
PP2A. For the first time it could be shown that in two lines 
responding with apoptosis to okadaic acid this response was 
associated with the rise of a tissue transglutaminase activity. 
An explanation for the discrepant reports on the involvement 
of transglutaminase activation accompanying apoptosis by 
okadaic acid might be the fast progression of okadaic acid 
induced apoptosis when compared to e.g. retinoic acid. In 
addition, cell-specific differences between the tested tumour 
lines are likely, e.g. their individual content of transglutami-
nase which differed even in the two investigated responsive 
lines. Thus, inhibitors of Ser/Thr PP1 and PP2A can be in-
cluded in the group of drugs inducing apoptosis with concom-
itant activation of a transglutaminase. 
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